Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331<sup>☆</sup>.

DR, Spigel; D, Vicente; TE, Ciuleanu; S, Gettinger; S, Peters; L, Horn; C, Audigier-Valette; Aranda N, Pardo; O, Juan-Vidal; Y, Cheng; H, Zhang; M, Shi; A, Luft; J, Wolf; S, Antonia; K, Nakagawa; J, Fairchild; C, Baudelet; D, Pandya; P, Doshi; H, Chang; M, Reck

doi:10.1016/j.annonc.2021.01.071

Public

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆.

Shared by NobleBlocks on Feb 1, 2021 • 12:00 AM UTC

Authors:

Spigel DR

Vicente D

Ciuleanu TE

Abstract

Background Patients with relapsed small-cell lung cancer (SCLC) have few treatment options and dismal survival. Phase I/II data show activity of nivolumab in previously treated SCLC.Patients and methods CheckMate 331 is a randomized, open-label, phase III trial of nivolumab versus standard chemother...

Subject

Immunotherapy

Biomarkers

PD-1

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!